Aggregator

对于对 NSAID 过敏的成年人来说,诱导阿司匹林耐受性的手术是一种有效的治疗方法吗?

5 months ago
对于对 NSAID 过敏的成年人来说,诱导阿司匹林耐受性的手术是一种有效的治疗方法吗? 关键信息 • 由于缺乏稳健的证据,作为对 NSAID 过敏患者的治疗选项,ATAD (通过让患者逐步接触药物来诱导对阿司匹林的耐受性)的好处与坏处仍不明确。 • ATAD 的治疗可能改善生活质量,但现有证据来自小型研究。 • 未来研究应该具备足够规模,以明确评估阿司匹林治疗对手术需求及类固醇使用的影响。 什么是非甾体类抗炎药加重的呼吸系统疾病? 非甾体类抗炎药加重的呼吸系统疾病是指对非甾体类抗炎药(如阿司匹林或布洛芬)过敏,伴随慢性鼻窦炎(鼻腔或鼻窦发炎,持续 12 周或更长时间),同时伴随或不伴随鼻息肉(鼻腔良性肿胀)或哮喘。非甾体类抗炎药加重的呼吸系统疾病的患者服用非甾体类抗炎药会在 30 min-120 min 内出现流鼻血、鼻塞、呼吸急促甚至舌头或喉咙肿胀等症状。这些症状可能轻微,也可能严重。 如何治疗非甾体类抗炎药加重的呼吸系统疾病? 非甾体类抗炎药加重的呼吸系统疾病患者通常伴有慢性鼻窦炎或哮喘或两者兼有。对于患有哮喘且需要药物治疗(反复使用口服皮质类固醇,即如泼尼松这类可减轻炎症的强效药物)的人,或因慢性鼻 - 鼻窦炎而反复接受手术的人,使用 ATAD 治疗可能有助于减轻症状,这些人同时患有严重慢性鼻 - 鼻窦炎。 本研究想要发现什么? 我们想要知道阿司匹林脱敏治对非甾体类抗炎药家...

虚拟现实干预是否比替代疗法或者无干预对多发性硬化患者效果更好?

5 months ago
虚拟现实干预是否比替代疗法或者无干预对多发性硬化患者效果更好? 关键信息 虚拟现实可以改善平衡与姿势控制、上肢功能、参与度和生活质量,但整体证据质量有限。 研究结果基于少量低质量证据,应该谨慎解读。 什么是多发性硬化? 多发性硬化是青年人群中最常见的神经系统疾病。多发性硬化患者会出现多种症状,例如疲乏、认知障碍和性功能障碍,此外还可能出现肌肉无力和协调问题。 虚拟现实技术如何帮助多发性硬化患者? 虚拟现实作为一种新的康复工具已经被越来越多地用于神经系统患者的康复。虚拟现实干预使用计算机程序,允许用户在虚拟环境中导航并与之互动。虚拟现实技术在康复领域的应用具有多种优势,例如可以提供完全可控的个性化环境和情境,而这些环境和情境在现实生活中过于危险、昂贵或不可能实现。此外,训练的难度和强度可以根据患者的技能进行调整,虚拟现实技术还可以通过创造更令人兴奋的训练环境和提供反馈来提高患者的积极性。 我们想要了解什么? 本综述旨在评估虚拟现实干预对多发性硬化症患者康复的有效性。我们希望了解使用虚拟现实技术进行训练是否会在下肢功能和步态、平衡和姿势控制、上肢功能、认知、疲劳、整体运动功能、活动受限、参与和生活质量以及不良(有害或不必要)事件的发生等方面带来更多改善。我们将虚拟现实训练与 1) 无干预、2) 传统疗法或替代疗法进行了比较。 我们做了什么? 我们找到 33 项研究,共包含1294名多...

Cochrane seeks Administrative Assistant

5 months 2 weeks ago

Title:  Administrative Assistant
Specifications: 12 month Fixed term contract – Full Time
Salary: £27,000 per annum
Location: (Remote) based in the UK, Germany or Denmark
Directorate: Evidence Production and Methods Directorate
Closing date: 10 January, 2025

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

This role provides effective and efficient administrative support the Cochrane Evidence Production & Methods Directorate (EPMD), primarily supporting the two Deputies and three Heads of the department.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

  • An opportunity to truly impact health globally
  • A flexible work environment
  • A comprehensive onboarding experiences
  • An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values. Cochrane has offices with payroll in the UK, Germany and Denmark.

How to apply

Monday, December 23, 2024 Category: Jobs
Harry Dayantis

Cochrane seeks Senior Administrative Officer (BGESC)

5 months 2 weeks ago

Title: Senior Administrative Officer (BGESC)
Specifications: 6 month Fixed term contract – Full Time
Salary: £35, 000 per annum
Location: (Remote) based in the UK, Germany or Denmark.
Directorate: Evidence Production and Methods Directorate
Closing date: 5 January, 2025

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.
As the BGESC Senior Administrative Officer, you will be key in providing high-level administrative, organizational, and logistical support to BGESC Project Manager, BGESC leadership team (four people) and to the Co-chairs of six international working/planning groups (approximately 20 people per group including Co-chairs).

This role is essential for ensuring the smooth execution of the ‘Building a Global Evidence Synthesis Community’ initiative, within a tight timeframe. By efficiently managing administrative tasks and optimizing processes, you will enable the Project Manager and leadership team to concentrate on strategic priorities and delivering key project milestones. The BGESC Administrative Officer will also provide support to BGESC Planning Clerks and Planning Analysts (nine people), who in turn work closely with the working/planning groups Co-chairs.

The BGESC project is part of the Wellcome Trust’s wider ‘Evidence Synthesis Infrastructure Collaborative’ initiative, but the successful candidate will be a Cochrane employee.

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organization is built on four core values: Collaboration: Underpins everything we do, locally and globally. Relevant: The right evidence at the right time in the right format. Integrity: Independent and transparent. Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

  • An opportunity to truly impact health globally
  • A flexible work environment
  • A comprehensive onboarding experiences
  • An environment where people feel welcome, heard, and included, regardless of their differences

Cochrane welcomes applications from a wide range of perspectives, experiences, locations and backgrounds; diversity, equity and inclusion are key to our values. Cochrane has offices with payroll in the UK, Germany and Denmark.

How to apply

Monday, December 23, 2024 Category: Jobs
Harry Dayantis

治疗女性不自主尿漏的最佳方法是什么?

5 months 2 weeks ago
治疗女性不自主尿漏的最佳方法是什么? 关键信息 - 一些对患有不自主(意外)漏尿的女性进行盆底肌(支撑膀胱、肠道和子宫的肌肉)训练的方法优于其他方法,一些方法可能效果相当。 - 我们对许多方法尚不确定,这往往是因为只有一项研究或几项小型研究在调查相关问题。 - 需要更多的研究来直接比较不同盆底肌训练的方法,尤其是研究不同的训练量(剂量)是否比其他方法更好——例如,每周进行更多或更少的训练。 什么是尿失禁? 盆底肌在两腿之间形成一个吊带,从骨盆前部的耻骨一直延伸到骨盆后部的尾骨。这个吊带支撑着膀胱、肠道和子宫。如果这些肌肉变得脆弱,女性可能无法控制膀胱中的尿液(小便)流出。这被称为尿失禁。尿失禁主要有三种类型。这三种类型分别是用力时漏尿(压力性尿失禁)、急需排空膀胱时漏尿(急迫性尿失禁)以及两者同时出现(混合性尿失禁)。本综述涵盖所有三种类型。尿失禁严重影响女性的生活质量。 什么是盆底肌训练? 通过训练提高盆底肌的力量、耐力和协调性可以减少漏尿。训练包括使用不同的方法(练习)或不同量(不同剂量)的相同方法。指导训练的方式也可以不同(例如,由一名临床医生指导一名女性,或由一名临床医生指导一组女性;或通过互联网、手机或传单进行练习)。 我们想知道什么? 我们想知道: - 某一种运动是否优于另一种运动; - 更高剂量的运动是否优于较低剂量的运动; - 对运动的更高强度监督是否优于低强度监...

针灸对出生时缺氧的婴儿(缺氧缺血性脑病)有哪些好处和坏处?

5 months 3 weeks ago
针灸对出生时缺氧的婴儿(缺氧缺血性脑病)有哪些好处和坏处? 关键信息 •由于缺乏证据,我们无法得出关于针灸对出生时缺氧(缺氧缺血性脑病)的婴儿的益处和伤害的任何结论。 •未来需要研究针灸的益处和伤害,也需要与药物进行比较,或比较不同的针灸使用方法。 缺氧缺血性脑病与针灸 婴儿出生前后缺氧时就会发生缺氧缺血性脑病,并可能导致严重疾病和死亡。有效的治疗选择是有限的。然而,三天的降温已被证明是有益的。针灸也已尝试用于治疗患有缺氧缺血性脑病的婴儿。针灸是中医学中的一种治疗方法。针(或激光)用于身体的特定(压力)点。人们相信,穴位可以改变身体内能量或生命力的流动,使其恢复平衡,从而预防疾病。它包括不同类型,例如带或不带电刺激的针灸、激光针灸、以及用手指代替针的非穿透式手动指压疗法。此外,针灸的持续时间和频率可能有所不同。 我们想知道什么? 我们想要找出针灸对患有缺氧缺血性脑病的婴儿的益处和伤害。我们的主要结局是死亡、18 至 24 个月和 3 至 5 岁儿童的长期大脑发育、不良事件和住院时间。 我们做了什么? 我们检索了将针灸与不治疗、安慰剂或假治疗(在科学研究中给予受试者的假治疗或假装治疗)、任何药物或其他类型针灸(例如,针灸与激光针灸相比)进行比较的研究。 我们发现了什么? 我们发现了四项研究,其中包括 464 名患有缺氧缺血性脑病的婴儿。研究规模从60到200名婴儿不等。三项研究在中...

对于早产且患有动脉导管未闭的婴儿,限制液体摄入有哪些优点和缺点?

5 months 3 weeks ago
对于早产且患有动脉导管未闭的婴儿,限制液体摄入有哪些优点和缺点? 关键信息 目前没有支持或反对减少液体作为早产儿动脉导管未闭治疗选项的证据。 我们需要随机对照临床试验来回答我们的问题,以帮助提供临床决策。 什么是动脉导管未闭 (PDA)? 动脉导管是婴儿出生前和出生后心脏和肺部之间的额外血管。为了使心脏和肺在出生后正常工作,这条血管必须关闭。在大多数婴儿中,动脉导管会在几天内自然闭合,他们的状况良好。 然而,在一些早产儿(孕周不足37周的婴儿)中,动脉导管会保持开放状态(称为动脉导管未闭)。这意味着多余的血液可能会流入肺部并引起问题(有症状)。这种病症称为动脉导管未闭(patent ductus arteriosus,PDA)。 可以通过减少给予这些婴儿的液体量来治疗 PDA。我们不确定减少给早产儿输液以减少 PDA 相关问题的益处和风险。 限制液体意味着什么? 限制液体摄入意味着限制无法母乳喂养或奶瓶喂养的婴儿的营养或药用液体的量。当婴儿无法通过口腔摄入任何东西时,他们的营养和药物将通过静脉(肠外营养)或通过管子插入胃部(肠内营养)给予。限制这种液体的量是治疗PDA婴儿的一种方法。 专家认为,限制液体摄入可能会改变心脏向全身泵血的方式,并减少心脏泵血所需的力度,从而有所帮助。然而,限制液体摄入量也可能有风险。一个风险是婴儿可能无法获得足够的营养。 我们想要了解什么? 我们想了解...

Update on ‘Exercise therapy for chronic fatigue syndrome’

5 months 3 weeks ago

In 2019, Cochrane published an amended version of the review 'Exercise therapy for chronic fatigue syndrome’ and, at that time, announced an intention to further update the review. Due to insufficient new research in the field and a lack of resources to oversee this work, the update will not be proceeding.

Any feedback on this decision should follow Cochrane’s established complaints process. Any correspondence sent directly to individuals at Cochrane will not be considered.

Monday, December 16, 2024
Harry Dayantis

女性移民与男性移民在获取、理解、评价和应用健康信息方面是否存在差异?

5 months 4 weeks ago
女性移民与男性移民在获取、理解、评价和应用健康信息方面是否存在差异? 关键信息 - 因关于男性移民的研究非常少,无法全面探讨女性移民与男性移民在获取、理解、评估和应用健康信息方面是否存在差异。 - 三项针对女性移民的研究表明,不同社区和文化中的性别角色会影响健康信息的获取、理解和应用方式。 我们想了解什么 我们的主要目标是找出移民(即移居国外)女性和男性在获取、理解、评估和应用健康信息方面是否存在差异。为了帮助我们理解证据,我们使用了一种称为“最佳拟合框架”的方法和一种称为“健康素养信息处理”的模型。健康信息处理的四个步骤—获取、理解、评估和应用健康信息—构成了我们所定义的一个人的“健康素养”。 我们做了什么 我们关注的是定性研究(例如,通过访谈或小组讨论让人们分享他们对某一健康话题的意见和看法的研究)。我们与本综述同时进行了一项其他综述,旨在了解不同干预措施在提高女性移民与男性移民健康素养方面的效果。然后,我们将该综述的结果与本综述的发现结合起来,解释性别和迁移特定因素在健康素养干预措施的开发和实施中可能发挥的作用。 对于这项质性综述,我们检索了与相关有效性评价中干预措施直接相关的质性研究。我们关注的是与有效性研究同时进行的研究。这些研究旨在探讨来自不同文化背景的人们对某一健康主题的看法和意见,以帮助构建干预措施,或探讨他们参与某项干预措施的体验。我们使用健康信息处理模型的四个...

静脉注射铁剂和口服铁剂治疗妊娠期缺铁性贫血的益处和风险是什么?

6 months ago
静脉注射铁剂和口服铁剂治疗妊娠期缺铁性贫血的益处和风险是什么? 关键信息 静脉注射铁剂可能比口服铁剂更能有效治疗妊娠期间因缺铁引起的贫血。 与口服铁剂比较,静脉注射铁剂对产后大量出血的影响可能很小甚至没有影响,并且对输血的需求可能也没有影响。 与口服铁剂比较,静脉注射铁剂的严重不良反应很少见,而且可能不会随静脉注射而增加。 什么是缺铁性贫血? 缺铁性贫血是一种影响血液输送氧气至全身的疾病。这是由于血液中铁含量不足引起的。当血液中缺乏铁时,身体就无法产生足够的血红蛋白,即将氧气输送到每个活细胞所需的分子。缺铁性贫血患者会感到乏力、虚弱、头痛、头晕和呼吸急促。 铁疗法如何治疗缺铁性贫血? 铁疗法有助于增加血液中可用铁的含量,因此可以提高血红蛋白水平,前提是没有其他贫血原因。铁疗法的两种主要形式是静脉注射(经静脉注射)和口服(经口)。这两类中存在多种制剂和多种形式的铁疗法,可用于治疗缺铁性贫血。 我们想了解什么? 我们想知道静脉注射铁剂在治疗妊娠期缺铁性贫血方面是否比口服铁剂更好,并探讨不同给药途径引起的任何不良反应。 我们做了什么 我们检索了所有比较静脉注射铁剂与口服铁剂对缺铁性贫血孕妇的影响的可用的研究,我们比较并总结了这些研究的结果,并根据研究方法和样本量等因素评估了证据的可信度。 我们发现了什么? 我们纳入了13项研究,共涉及3939名患有缺铁性贫血的孕妇。大多数研究调查了女性...

£10 million global consortium to advance evidence synthesis in climate and health

6 months ago

Cochrane is part of a new global consortium to develop new tools, powered by artificial intelligence (AI), to analyse and synthesise research evidence on the relationships between climate change and human health.

The consortium is supported by a £10.2 million grant from Wellcome over four years, led by the Berlin-based climate research institute MCC.

The DESTINY project will develop novel AI-driven tools to make evidence synthesis faster, more efficient and continuously updated. The tools aim to automate and streamline tasks such as detecting relevant individual studies, extracting and synthesising their respective findings and identifying overarching insights.

As an internationally-recognised leader in evidence synthesis for human health, Cochrane will help to apply our methodological expertise to the field of climate research. We will co-lead several work programmes with the Campbell Collaboration, who specialize in evidence synthesis for social research.

It will be vital to ensure that outputs from automated tools are responsible and robust, with human oversight offering safeguards and methodological expertise. Cochrane will co-lead this workstream with Campbell, defining standards for responsible AI use and producing best-practice guidance. We will also help to ensure that the technology can be used equitably across the world, working with our extensive global network and consortium partners to build and strengthen capacity.

“Climate change poses one of the greatest threats to human health, so this project is both vital and timely,” says Dr Karla Soares-Weiser, Editor-in-Chief of the Cochrane Library and co-Principal Investigator on the DESTINY project. “It has the potential to transform evidence synthesis for climate and health, equipping decision-makers with the evidence they need to make informed decisions. Climate change is a key research priority in Cochrane’s scientific strategy, while methodological innovation is one of our core commitments. The DESTINY project will enable us to further these goals in collaboration with partners across the world, all bringing our own strengths to deliver the best outcomes.”

The project takes place in the context of a wider investment into evidence synthesis infrastructure, with £54.2 million of funding announced in September from both Wellcome and the UK government. The DESTINY grant is a separate award focused on climate change and health, signalling Wellcome’s leadership in this area.

“Stopping climate change is critical for securing human health,” says Jan Minx, head of the MCC working group Applied Sustainability Science and principal investigator of the DESTINY project. “Policymakers need the best and most recent scientific evidence to support their decisions, but the ready-to-hand evidence is often anecdotal and outdated. This project is pushing the boundaries of what is possible by using the latest advances in AI. It will demonstrate that the scientific knowledge needed for health-centred climate action can be synthesised and provided almost instantly. Speed and scientific rigour can go hand in hand – this is key to efficiently solving the big issues of our time.”

The consortium partners are Cochrane, University College London, The London School of Hygiene & Tropical Medicine, the ACRES Center for Rapid Evidence Synthesis, Future Evidence Foundation, the African Synthesis Centre for Climate Change, Environment and Development, Effective Basic Services (eBase) Africa, the Campbell Collaboration. “Having a diverse community of partners will ensure equity and inclusion in global evidence infrastructures,” says Patrick Okwen, Co-Investigator from eBase Africa.

Friday, December 6, 2024
Harry Dayantis

Cochrane seeks Assistant Quality Assurance Editor

6 months ago

Title: Assistant Quality Assurance Editor
Specifications: Permanent – Full Time
Salary: £30,000 per annum
Location: (Remote) based in the UK, Germany or Denmark
Directorate: Evidence Production and Methods Directorate
Closing date: 17 December 2024

Cochrane is an international charity. For 30 years we have responded to the challenge of making vast amounts of research evidence useful for informing decisions about health. We do this by synthesising research findings and our work has been recognised as the international gold standard for high quality, trusted information.

As Assistant Quality Assurance Editor within Cochrane’s Editorial Department, you will provide support to the Quality Assurance Editor and Senior Quality Assurance Editor, to help them to assess whether protocols, reviews and updates submitted to Cochrane’s Central Editorial Service have met Cochrane’s methodological standards. The post holder will provide this support by gathering information on individual reviews (e.g., by performing initial checks on submitted reviews, identifying and accessing relevant papers, or performing consistency checks within the reviews), assisting with the write up of peer review reports, and helping the Quality Assurance Team to reach consensus on recommendations to make for each submission.

You will also be trained to conduct your own full assessments of protocols, reviews and updates submitted to Cochrane’s Central Editorial Service have met Cochrane’s methodological standards, with the possibility of moving up a level to the role of ‘Quality Assurance Editor’ at a future stage. 

Don’t have every single qualification? We know that some people are less likely to apply for a job unless they are a perfect match. At Cochrane, we’re not looking for “perfect matches.” We’re looking to welcome people to our diverse, inclusive, and passionate workplace. So, if you’re excited about this role but don’t have every single qualification, we encourage you to apply anyway. Whether it’s this role or another one, you may be just the right candidate.

Our organisation is built on four core values:

Collaboration: Underpins everything we do, locally and globally.

Relevant: The right evidence at the right time in the right format.

Integrity: Independent and transparent.

Quality: Reviewing and improving what we do, maintaining rigour and trust.

You can expect:

  • An opportunity to truly impact health globally.
  •   A flexible work environment
  • A comprehensive onboarding experiences.
  •  An environment where people feel welcome, heard, and included, regardless of their differences.

Cochrane welcomes applications from a wide range of perspectives, experiences, locations, and backgrounds; diversity, equity and inclusion are key to our values.

How to apply

  •  For further information on the role and click “how to apply”.
  • The deadline to receive your application is 17 December, 2024.
  • The supporting statement should indicate why you are applying for the post, and how far you meet the requirements, using specific examples.
  • Read our Recruitment Privacy Statement
Thursday, December 5, 2024 Category: Jobs
Mia Parkinson

哪种化疗方法对晚期胰腺癌患者最有效?

6 months ago
哪种化疗方法对晚期胰腺癌患者最有效? 关键信息 • 与单用吉西他滨相比,FOLFIRINOX 和吉西他滨联合紫杉烷可延长晚期胰腺癌患者的生命。 • 我们的研究结果表明,与吉西他滨加紫杉烷相比,基于氟嘧啶的联合化疗可以延长晚期胰腺癌患者的生命。 什么是胰腺癌? 胰腺癌是一种高度侵袭性的癌症,通常在无法进行手术的晚期才被确诊。早期通常没有症状,但晚期可能出现腹痛、体重减轻、恶心、厌食、皮肤和眼睛发黄等症状。当晚期确诊时,治疗方法包括化疗(杀死癌细胞或减缓其生长的药物)、放射疗法(X 射线治疗)或其他药物。这些治疗旨在控制癌症相关症状并延长患者的生命,但不能治愈。全世界越来越多的人被诊断出患有胰腺癌,因此本综述对于了解治疗晚期胰腺癌的最佳方法非常重要。 我们想知道什么? 本综述旨在找出对晚期、无法治愈的胰腺癌最有效的治疗方法。我们还想确定这些治疗的副作用。 我们做了什么? 我们检索了所有针对以下胰腺癌患者的研究:(1)局部晚期,即癌症已从胰腺扩散到附近组织;或(2)转移性,即癌症已扩散到身体其他部位。我们收集了患者的总体生存时间(因任何原因死亡的时间)、副作用和生活质量的数据。我们对研究结果进行了比较和总结,并根据研究方法和规模等因素对证据的可信度进行了评级。 我们发现了什么? 本综述共纳入了75项研究,涉及 11,333名受试者。这些研究将一种疗法与最佳支持治疗(仅对症治疗)或另一种...